XML 90 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements Of Changes In Stockholders' Deficit - USD ($)
Total
Series A [Member]
Series B [Member]
Common Stock [Member]
Series A [Member]
Common Stock [Member]
Series B [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Balance, Shares at Dec. 31, 2021       0 7,503,750    
Balance at Dec. 31, 2021 $ 23,207     $ 0 $ 750 $ 24,250 $ (1,793)
Sale of 13,850,000 Private Placement Warrants 13,850,000         13,850,000  
Forfeiture of Founder Shares, Shares         (3,750)    
Compensation Expense – Fair value of assigned Founder Shares to Apeiron 362,500         362,500  
Fair value of Public Warrants at issuance 8,100,000         8,100,000  
Allocated value of transaction costs to Series A common stock (505,049)         (505,049)  
Remeasurement of Series A common stock to redemption amount (33,896,988)         (21,831,701) (12,065,287)
Net income (loss) 886,918 $ 701,826 $ 185,092       886,918
Balance, Share at Dec. 31, 2022       0 7,500,000    
Balance at Dec. 31, 2022 (11,179,412)     $ 0 $ 750 0 (11,180,162)
Remeasurement of Series A common stock to redemption amount (4,395,161)           (4,395,161)
Stockholder non-redemption agreement 1,378,126         1,378,126  
Stockholder non-redemption agreement (1,378,126)         (1,378,126)  
Excise tax (3,062,004)           (3,062,004)
Conversion of Series Class B shares to Series Class A Non-redeemable shares, Shares       7,499,999 (7,499,999)    
Conversion of Series Class B shares to Series Class A Non-redeemable shares       $ 749 $ (749)    
Net income (loss) 2,821,459           2,821,459
Balance, Share at Dec. 31, 2023       7,499,999 1    
Balance at Dec. 31, 2023 $ (15,815,118)     $ 749 $ 1 $ 0 $ (15,815,868)